The simplest form of stimulation is carried out using clomiphene citrate, often abbreviated as CC. Alternatively, nowadays the active pharmaceutical ingredient Letrozole can also be used and has shown itself to be more beneficial than Clomiphene in several studies. However, the use in fertility treatment continues to be on an off-label basis (outside of the range of use for which it was originally approved). The use of both medications in tablet form usually takes place during days 5-9 of the menstrual cycle and results in increased FSH (follicle stimulating hormone) production. The growth of the follicle is then monitored via ultrasound and, if necessary, blood hormone level testing.
After a follicle size of between 18-20 mm has been reached, then the ovulation can be triggered using an “ovulation injection”. Approximately 24-32 hours later, the suitably processed sperm can be placed into the uterine cavity (intrauterine insemination IUI). The pregnancy rate is reported at 10-15% per treatment cycle and depends greatly on the age of the woman and the spermiogram findings.
Intravaginal insemination provides no advantage compared with sexual intercourse and is therefore without therapeutic significance.
The statutory health insurance providers only subsidise clomiphene stimulation during UNSTIMULATED cycles. This should be considered when applying for cost coverage (partial cost coverage).